Evidence map›Paper›PMID 39822771›Full record

ArticleCoordination chemistry reviews2024

Control of metalloenzyme activity using photopharmacophores.

Noushaba Nusrat Mafy, Dorothea B Hudson, Emily L Que

Abstract read
In one paragraph

Article in Coordination chemistry reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Noushaba Nusrat MafyDepartment of Chemistry, University of Texas at Austin, 105 E 24th St, Austin, TX 78712, United States.
Dorothea B HudsonDepartment of Chemistry, University of Texas at Austin, 105 E 24th St, Austin, TX 78712, United States.
Emily L QueDepartment of Chemistry, University of Texas at Austin, 105 E 24th St, Austin, TX 78712, United States.

Funding

Targeted molecular strategies for cellular investigation of metalloproteinsR35GM133612 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Emily L Que · 2019 to 2026
$2.8M
NIGMS NIH HHS R35 GM133612
6 · The paper itself

Abstract

Metalloenzymes are responsible for numerous physiological and pathological processes in living organisms; however, there are very few FDA-approved metalloenzyme-targeting therapeutics (only ~ 67 FDA-approved metalloenzyme inhibitors as of 2020, less than ~ 5 % of all FDA-approved therapeutics). Most metalloenzyme inhibitors have been developed to target the catalytic metal centers in metalloenzymes

Indexed as

InhibitorLight activationMetal binding groupsMetalloenzymePhotopharmacophore

Identifiers

PMID39822771
PMCPMC11737041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.